G. Denton

598 total citations
21 papers, 478 citations indexed

About

G. Denton is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, G. Denton has authored 21 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 10 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in G. Denton's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Glycosylation and Glycoproteins Research (10 papers) and Immunotherapy and Immune Responses (5 papers). G. Denton is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Glycosylation and Glycoproteins Research (10 papers) and Immunotherapy and Immune Responses (5 papers). G. Denton collaborates with scholars based in United Kingdom, Australia and Switzerland. G. Denton's co-authors include J D Hardcastle, Lindy G. Durrant, R. A. Robins, Eric Austin, M.R. Price, Herb F. Sewell, Alan C. Perkins, M.C. Bishop, M. Frier and Helen Denley and has published in prestigious journals such as Journal of Clinical Oncology, Annals of the New York Academy of Sciences and British Journal of Cancer.

In The Last Decade

G. Denton

21 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Denton United Kingdom 14 250 222 221 150 52 21 478
Hiroki Shomura Japan 12 68 0.3× 299 1.3× 211 1.0× 264 1.8× 37 0.7× 32 455
G. Pusztaszeri United States 6 212 0.8× 59 0.3× 189 0.9× 124 0.8× 45 0.9× 13 395
Sheri McMahon United States 10 51 0.2× 299 1.3× 108 0.5× 347 2.3× 30 0.6× 31 478
Seiji Hosaka Japan 7 57 0.2× 143 0.6× 266 1.2× 140 0.9× 42 0.8× 20 538
N Hozumi Canada 14 70 0.3× 216 1.0× 224 1.0× 101 0.7× 36 0.7× 21 482
Robin Marsden United States 7 158 0.6× 143 0.6× 168 0.8× 142 0.9× 34 0.7× 8 436
Kersti Klaamas Estonia 12 215 0.9× 277 1.2× 275 1.2× 58 0.4× 111 2.1× 23 463
Yoshitomo Ozaki Japan 12 26 0.1× 185 0.8× 154 0.7× 182 1.2× 55 1.1× 42 400
Oleg Kurtenkov Estonia 14 260 1.0× 321 1.4× 341 1.5× 61 0.4× 121 2.3× 34 544
Kazunori Yokomine Japan 10 38 0.2× 236 1.1× 283 1.3× 205 1.4× 40 0.8× 18 503

Countries citing papers authored by G. Denton

Since Specialization
Citations

This map shows the geographic impact of G. Denton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Denton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Denton more than expected).

Fields of papers citing papers by G. Denton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Denton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Denton. The network helps show where G. Denton may publish in the future.

Co-authorship network of co-authors of G. Denton

This figure shows the co-authorship network connecting the top 25 collaborators of G. Denton. A scholar is included among the top collaborators of G. Denton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Denton. G. Denton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heuser, Christoph, et al.. (2003). An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. British Journal of Cancer. 89(6). 1130–1139. 31 indexed citations
2.
Perkins, Alan C., M. Frier, M. L. Wastie, et al.. (2001). Imaging for staging bladder cancer: a clinical study of intravenous 111 indium‐labelled anti‐MUC1 mucin monoclonal antibody C595. British Journal of Urology. 87(1). 39–46. 19 indexed citations
3.
Bishop, M.C., Alan C. Perkins, M. L. Wastie, et al.. (2000). Targeting Superficial Bladder Cancer by the Intravesical Administration of Copper-67–Labeled Anti-MUC1 Mucin Monoclonal Antibody C595. Journal of Clinical Oncology. 18(2). 363–363. 56 indexed citations
4.
Spencer, Daniel I. R., Sotiris Missailidis, G. Denton, et al.. (1999). Structure/activity studies of the anti‐MUC1 monoclonal antibody C595 and synthetic MUC1 mucin‐core‐related peptides and glycopeptides. Biospectroscopy. 5(2). 79–91. 21 indexed citations
5.
Nair, Madhu K., John B. Ludlow, Donald A. Tyndall, Enrique Platín, & G. Denton. (1998). Periodontitis detection efficacy of film and digital images. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology. 85(5). 608–612. 30 indexed citations
6.
Murray, Alan, et al.. (1998). Design of ligands for the purification of anti‐MUC1 antibodies by peptide epitope affinity chromatography. Journal of Peptide Research. 52(5). 375–383. 13 indexed citations
7.
Bishop, M.C., Alan C. Perkins, M. Frier, et al.. (1997). Preclinical evaluation of copper-67 labelled anti-MUC1 mutin antibody C595 for therapeutic use in bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging. 24(4). 439–443. 29 indexed citations
8.
Denton, G., et al.. (1997). Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas. British Journal of Cancer. 76(5). 614–621. 19 indexed citations
9.
Price, M.R., et al.. (1997). Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging. 24(4). 439–443. 22 indexed citations
10.
Denton, G., et al.. (1995). Primary sequence determination and molecular modelling of the variable region of an antiMUC1 mucin monoclonal antibody. European Journal of Cancer. 31(2). 214–221. 2 indexed citations
11.
Denton, G., Ferenc Hudecz, Judit Kajtár, et al.. (1995). Sequential order of T and B cell epitopes affects immunogenicity but not antibody recognition of the B cell epitope.. PubMed. 7(5). 258–64. 9 indexed citations
12.
Smyth, John F., J D Hardcastle, G. Denton, et al.. (1995). Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer. Annals of Oncology. 6(9). 948–949. 24 indexed citations
13.
Denton, G., Lindy G. Durrant, J D Hardcastle, et al.. (1994). Clinical outcome of colorectal cancer patients treated with human monoclonal anti‐idiotypic antibody. International Journal of Cancer. 57(1). 10–14. 56 indexed citations
14.
15.
Durrant, Lindy G., Timothy J. Buckley, G. Denton, et al.. (1994). Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7.. PubMed. 54(18). 4837–40. 31 indexed citations
16.
Durrant, Lindy G., G. Denton, & R. A. Robins. (1993). Immunization with Human Monoclonal Antiidiotypic Antibody in Colorectal Cancer. Annals of the New York Academy of Sciences. 690(1). 334–336. 2 indexed citations
17.
Denton, G., et al.. (1993). Induction of antibody responses to breast carcinoma associated mucins using synthetic peptide constructs as immunogens. Cancer Letters. 70(3). 143–150. 16 indexed citations
18.
Durrant, Lindy G., G. Denton, Elizabeth R. Jacobs, et al.. (1992). An idiotypic replica of carcinoembryonic antigen inducing cellular and humoral responses directed against human colorectal tumours. International Journal of Cancer. 50(5). 811–816. 30 indexed citations
19.
Denton, G., W A Brough, & D E F Tweedle. (1991). Pancreaticojejunostomy For Severe Symptomatic Chronic Pancreatitis. HPB Surgery. 5(2). 117–122. 2 indexed citations
20.
Robins, R. A., G. Denton, J D Hardcastle, et al.. (1991). Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.. PubMed. 51(19). 5425–9. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026